Registered entities
Protagonist Therapeutics, Inc
Reg. No. 1377121United States
Protagonist Therapeutics Inc.
Reg. No. 98-0505495Belgium
Innovation
58 patent families (21 granted) — focus: Chemistry & metallurgy, Human necessities, Electricity & electronics, Physics & computing; filing pace steady. Cited 12,543 times.
| Year | Filings |
|---|---|
| 2015 | 5 |
| 2016 | 8 |
| 2017 | 12 |
| 2018 | 13 |
| 2019 | 16 |
| 2020 | 16 |
| 2021 | 16 |
| 2022 | 20 |
| 2023 | 27 |
| 2024 | 27 |
| 2025 | 28 |
| 2026 | 7 |
Social engagement
Social engagement: 9.6K social following, 9 posts in the last 12 months — below the industry typical range.
Investor mix
14 investors on record; lead investors include Canaan, Lilly Ventures, Johnson & Johnson Innovation – JJDC; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 50% |
| Private equity | 1 | 7% |
| Other / undisclosed | 6 | 43% |
Recent activity
3 Jun 2026
Event
Jefferies Global Healthcare Conference
1 Jun 2026
Event
2026 European Hematology Association Congress (EHA2026 Congress)
15 May 2026
Event
TIDES: Oligonucleotides and Peptide Therapeutics USA 2026